immunotherapy

Oncology

Harnessing IL-12: Immunotherapy research advances may enhanc...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer recurrence, more effective disease maintenance strategies, more preci

R&D

Jeffrey Meckler having an interview with Jonah Comstock

Reuters Pharma USA 2024 – Jeffrey Meckler

Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

News